C2 Pharma Announces Launch of New API, Oxybuprocaine Hydrochloride, Enhancing Pain Management Solutions

11 March 2024 | Monday | News

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), is excited to announce the upcoming launch of their new API, Oxybuprocaine HCL, an API that will be manufactured by our manufacturing partner Laurus Labs. The addition of this API will extend our range of high-quality Ophthalmic APIs and strengthen our commitment to meeting the market's evolving needs.
Image Source : Public Domain

Image Source : Public Domain

Oxybuprocaine (also known as Benoxinate), is a local topical anesthetic used especially in ophthalmology and otolaryngology for short term medical procedures. We are completing the validation process, by April 2024, and upon completion, GMP samples will be available to our customers worldwide for evaluation and testing.

We expect to submit a Certificate of Suitability (CEP) by May 2024, a US-Drug Master File (US-DMF) by August 2024, and a Certificate of Acceptance of Drugs and Food (CADIFA) in Q4 of 2024.

“At C2 PHARMA, we understand the importance of being able to deliver ophthalmic APIs meeting the highest quality standards and the best cost-to-quality and cost-to-reliability in the industry. We are committed to providing our customers with the most dependable service level for ophthalmic APIs.” states Andrew Badrot, CEO of C2 PHARMA. “We will further be expanding our range of high-quality Ophthalmic-APIs throughout 2024, with our next release being Naphazoline Hydrochloride.”

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in